BALAXI PHARMACEUTICALS LIMITED

rs,

etary & Compliance Officer Encl: A/a Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase Ill, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC12

400 billion

et Targeted Expansion Product Sourcing Regions Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 12 Key Milestones Started business supplying white labelled p

6 billion

cing Regions Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 12 Key Milestones Started business supplying white labelled products to customers in Africa P

INR 47.57 crore

onduras and El Salvador Successfully completed fund raising exercise through Preferential issue – INR 47.57 crore Capex plans – Established Company’s first pharma formulation manufacturing facility in Hyderabad

₹56.17 crore

ent’s Comments – Q2 FY26 Performance “Q2 FY26 was a challenging quarter, with revenue declining to ₹56.17 crore from ₹77.38 crore in the same period last year, reflecting a 27% YoY decrease. The decline was pri

₹77.38 crore

2 FY26 Performance “Q2 FY26 was a challenging quarter, with revenue declining to ₹56.17 crore from ₹77.38 crore in the same period last year, reflecting a 27% YoY decrease. The decline was primarily driven by s

27%

ith revenue declining to ₹56.17 crore from ₹77.38 crore in the same period last year, reflecting a 27% YoY decrease. The decline was primarily driven by softer market demand, pressure on working capital

48%

ity across key markets. Despite these headwinds, the gross profit margin remained strong at above 48%, highlighting the resilience of our branded generics portfolio. The bottom line declined sharply t

₹0.21 crore

highlighting the resilience of our branded generics portfolio. The bottom line declined sharply to ₹0.21 crore (vs ₹4.59 crore last year), mainly due to higher operational costs linked to our strategic shift t

₹4.59 crore

resilience of our branded generics portfolio. The bottom line declined sharply to ₹0.21 crore (vs ₹4.59 crore last year), mainly due to higher operational costs linked to our strategic shift to institutional

48.3%

Margin Profit After Tax PAT Margin % Earning Per Share (in Rs.) Q2 FY26 Q2 FY25 56.17 27.14 48.3% 1.17 2.1% 0.21 0.4% 0.04 77.38 33.21 42.9% 10.59 13.7% 4.59 5.9% 0.84 YoY (27.4%) (1

2.1%

it After Tax PAT Margin % Earning Per Share (in Rs.) Q2 FY26 Q2 FY25 56.17 27.14 48.3% 1.17 2.1% 0.21 0.4% 0.04 77.38 33.21 42.9% 10.59 13.7% 4.59 5.9% 0.84 YoY (27.4%) (18.3%) +540

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“16 FINANCIAL HIGHLIGHTS 17 Management’s Comments – Q2 FY26 Performance “Q2 FY26 was a challenging quarter, with revenue declining to ₹56.17 crore from ₹77.38 crore in the same period last year, reflecting a 27% YoY decrease.”

Registered Office

1

Expansion initiated

1

Registered Office

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase Ill, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 I Email: info@balaxi.in I Website: www.balaxipharma.in Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Balaxi Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. 2 Contents 04 Corporate Snapshot 17 Financial Highlights 23 Str

Expansion initiated

Ecuador, Chile (Latin America) 935 product registrations in Seven countries 200+ registrations submitted or in the pipeline Established the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools 5 Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-English speaking countries with similar characteristics  Low competitive intensity and potential to establish top-2 position  On-ground feedback mechanism allows deep understanding of demand dynamics  As population crosses prosperity thresholds, healthcare spends expand exponentially Human Capital Management  Established unique ecosystem of 100+ Indian expatriates in operating geographies  Financial security ecosystem for key personnel, creating